The FDA has recorded a Class III recall of olanzapine 5 mg tablets in 30-count bottles distributed in the US by Macleods Pharma USA and manufactured by Macleods Pharmaceuticals in India. The reason given is organic and unspecified impurities above specification. The recall was listed as ongoing.
Class III is the lowest tier: the FDA uses it where the product is unlikely to cause adverse health consequences. It is a manufacturing quality action, not a new safety finding about olanzapine.
The US recall does not by itself say anything about products sold in India, and we have no information on any CDSCO action. Patients should not stop olanzapine because of this notice; abrupt discontinuation carries its own risks.
- Advise patients not to stop olanzapine on the strength of this notice.
- Check the manufacturer if a patient brings a recall query, since this concerns one firm's tablets.
- Treat this as a quality defect, not a change in olanzapine's safety profile.
- Watch for any CDSCO notice on the Indian supply; none is known at present.
Why it matters
Patients often see recall headlines and stop medication abruptly.
Don't overread it
A Class III recall is a quality action, not evidence that the drug harmed anyone.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free